Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer
Open Access
- 17 September 2004
- journal article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 11 (11) , 748-756
- https://doi.org/10.1038/sj.cgt.7700753
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Endogenous p21WAF1/CIP1 status predicts the response of human tumor cells to wild-type p53 and p21WAF1/CIP1 overexpressionCancer Gene Therapy, 2003
- RNA interference in adult miceNature, 2002
- Downregulating PKC δ provides a PI3K/Akt-independent survival signal that overcomes apoptotic signals generated by c-Src overexpressionOncogene, 2002
- Apoptosis in the absence of caspase 3Oncogene, 2001
- A Novel mRNA–cDNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP CellsBiochemical and Biophysical Research Communications, 2001
- Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with ApoptosisJournal of Biological Chemistry, 1998
- The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of ApoptosisScience, 1997
- Molecular Ordering of the Cell Death Pathway: Bcl-2 AND Bcl-xL FUNCTION UPSTREAM OF THE CED-3-LIKE APOPTOTIC PROTEASESPublished by Elsevier ,1996
- High levels of transglutaminase expression in doxorubicin‐resistant human breast carcinoma cellsInternational Journal of Cancer, 1994
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992